Safety and quality of life of CDK4/6 inhibitors therapy for hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: a multicenter cross-sectional survey in China
The safety profile of different CDK4/6i varies and has different impacts on patients' quality of life, which needs more attention in clinical practice.
Authors
- Haibo Wang (ORCID: https://orcid.org/0000-0002-7514-1719)
- Hongyuan Li (ORCID: https://orcid.org/0000-0001-9119-5592)
- Zhaofeng Niu
- Hao‐Qi Wang
- Xueqiang Gao
- Benlong Yang
- Zheyu Hu
- Linxiaoxi Ma
- Zhongsheng Tong (ORCID: https://orcid.org/0000-0001-8060-5699)
- Shu Wang (ORCID: https://orcid.org/0000-0002-8651-4795)
- Cuizhi Geng (ORCID: https://orcid.org/0000-0001-5541-5412)
- Zhengkui Sun
- Yong Shen (ORCID: https://orcid.org/0000-0002-9646-164X)
- Yiding Chen (ORCID: https://orcid.org/0000-0002-2263-6275)
- Jiong Wu (ORCID: https://orcid.org/0000-0002-8103-0505)
- Xuming Wang (ORCID: https://orcid.org/0000-0002-2266-8816)
- Fei Xie (ORCID: https://orcid.org/0000-0002-3636-2682)
- Quchang Ouyang (ORCID: https://orcid.org/0000-0003-1233-6081)
- Qiao Cheng
- Mu Tang (ORCID: https://orcid.org/0000-0001-5102-4983)
Institutions
- Qingdao University (CN)
- Hebei Medical University (CN)
- Peking University (CN)
- Tianjin Medical University Cancer Institute and Hospital (CN)
- Jiangxi Provincial Cancer Hospital (CN)
- Fourth Hospital of Hebei Medical University (CN)
- Hunan Cancer Hospital (CN)
- Affiliated Hospital of Qingdao University (CN)
- Peking University People's Hospital (CN)
- The Affiliated Yongchuan Hospital of Chongqing Medical University (CN)
- Second Affiliated Hospital of Zhejiang University (CN)
- Chongqing Medical University (CN)
Publication Details
- Journal
- BMC Cancer
- Published
- 2025-05-27
- DOI
- https://doi.org/10.1186/s12885-025-14223-8
- Citations
- 1
- Primary Topic
- Advanced Breast Cancer Therapies
- Type
- article
- Field-Weighted Citation Impact
- 1.52